© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Insight Molecular Diagnostics Inc. (IMDX) stock declined over -0.46%, trading at $4.32 on NASDAQ, down from the previous close of $4.34. The stock opened at $4.37, fluctuating between $4.23 and $4.37 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | 4.37 | 4.46 | 4.20 | 4.32 | 83.1K |
| Aug 21, 2026 | 4.40 | 4.46 | 4.31 | 4.34 | 38.69K |
| Aug 20, 2026 | 4.36 | 4.43 | 4.20 | 4.30 | 112.16K |
| Aug 19, 2026 | 4.29 | 4.50 | 4.25 | 4.38 | 146.93K |
| Aug 18, 2026 | 4.22 | 4.35 | 4.09 | 4.28 | 318.06K |
| Aug 17, 2026 | 4.29 | 4.37 | 4.01 | 4.27 | 97.07K |
| Aug 14, 2026 | 3.76 | 4.36 | 3.76 | 4.32 | 331.64K |
| Aug 13, 2026 | 4.47 | 4.49 | 3.54 | 3.71 | 1.16M |
| Aug 12, 2026 | 4.48 | 4.50 | 4.15 | 4.50 | 279.64K |
| Aug 11, 2026 | 4.60 | 4.88 | 4.20 | 4.43 | 522.32K |
| Aug 10, 2026 | 4.85 | 4.93 | 4.76 | 4.77 | 73.26K |
| Aug 07, 2026 | 4.85 | 4.93 | 4.70 | 4.83 | 41.98K |
| Aug 06, 2026 | 4.92 | 5.06 | 4.66 | 4.80 | 133.47K |
| Aug 05, 2026 | 5.23 | 5.26 | 4.90 | 5.00 | 107.3K |
| Aug 04, 2026 | 5.11 | 5.32 | 5.03 | 5.12 | 200.17K |
| Aug 03, 2026 | 4.73 | 5.22 | 4.61 | 5.03 | 293.26K |
| Jul 31, 2026 | 4.60 | 4.71 | 4.45 | 4.65 | 61.61K |
| Jul 30, 2026 | 4.41 | 4.66 | 4.41 | 4.60 | 95.47K |
| Jul 29, 2026 | 4.59 | 4.60 | 4.35 | 4.37 | 124.57K |
| Jul 28, 2026 | 4.69 | 4.78 | 4.50 | 4.61 | 128.43K |
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
| Employees | 57 |
| Beta | 1.82 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |